Despite the low PD-L1 CPS, the patient’s dMMR status likely contributed to a high TMB, driving the favorable response to nivolumab plus chemotherapy, consistent with Jiang et al.’s findings of improved survival in PMS2-deficient ESCC [12]. Here, PMS2 is linked to esophageal squamous cell carcinoma.